HomeCompareSLRX vs PLD

SLRX vs PLD: Dividend Comparison 2026

SLRX yields 238.10% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRX wins by $333.09M in total portfolio value
10 years
SLRX
SLRX
● Live price
238.10%
Share price
$0.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$339.60M
Annual income
$185,958,933.65
Full SLRX calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — SLRX vs PLD

📍 SLRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRX
Annual income on $10K today (after 15% tax)
$20,238.10/yr
After 10yr DRIP, annual income (after tax)
$158,065,093.60/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, SLRX beats the other by $153,597,122.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRX + PLD for your $10,000?

SLRX: 50%PLD: 50%
100% PLD50/50100% SLRX
Portfolio after 10yr
$173.05M
Annual income
$95,607,684.91/yr
Blended yield
55.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

SLRX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-14.5
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRX buys
0
PLD buys
0
No recent congressional trades found for SLRX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRXPLD
Forward yield238.10%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$339.60M$6.50M
Annual income after 10y$185,958,933.65$5,256,436.18
Total dividends collected$322.91M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SLRX vs PLD ($10,000, DRIP)

YearSLRX PortfolioSLRX Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$34,510$23,809.52$11,255$555.24+$23.3KSLRX
2$113,715$76,790.22$13,062$1,018.59+$100.7KSLRX
3$358,160$236,484.38$15,903$1,926.67+$342.3KSLRX
4$1,079,339$696,107.48$20,839$3,823.32+$1.06MSLRX
5$3,115,421$1,960,529.07$30,464$8,166.08+$3.08MSLRX
6$8,622,197$5,288,696.04$52,054$19,457.30+$8.57MSLRX
7$22,905,117$13,679,366.22$109,886$54,188.93+$22.80MSLRX
8$58,470,750$33,962,275.23$304,030$186,451.18+$58.17MSLRX
9$143,588,724$81,025,021.41$1,166,125$840,813.32+$142.42MSLRX
10$339,598,869$185,958,933.65$6,504,190$5,256,436.18+$333.09MSLRX

SLRX vs PLD: Complete Analysis 2026

SLRXStock

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Full SLRX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this SLRX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRX vs SCHDSLRX vs JEPISLRX vs OSLRX vs KOSLRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.